Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026

The October 2026 CHMP highlights record two withdrawn applications for extensions of indication, for Ibrance (palbociclib) in HER2-positive breast cancer maintenance and Truqap (capivasertib) in PTEN-deficient metastatic hormone-responsive prostate cancer. Withdrawal is a strategic decision, not simply a failure.

Why companies withdraw

An applicant may withdraw at any stage before the Committee adopts its opinion. Typical reasons include an anticipated negative outcome, a need for additional data that cannot be provided within the clock, or a change in commercial or clinical priorities. EMA publishes withdrawal information and, for new-indication variations, an assessment report is normally made available.

What a withdrawal does and does not do

  • The authorised indications are unaffected. The existing marketing authorisation continues unchanged.
  • Resubmission remains possible. A new application can follow once the evidence gap has been addressed.
  • The record is public. Clinicians, payers and competitors can read why the application stalled.

Lessons for planning an extension

Extensions of indication are Type II variations and are scrutinised for the strength of the pivotal evidence, the relevance of the comparator and the clinical meaning of the endpoint. Early scientific advice on the proposed wording, subgroup definition and biomarker strategy is often more valuable than late-stage rescue.

Withdrawal versus waiting

Withdrawing can be better than receiving a negative opinion, because it preserves flexibility. The decision should be taken with full awareness of the timetable, the consequences for any linked national procedures and the effect on ongoing HTA work, where the indication was the basis of a reimbursement case.

How PQRA helps

PQRA advises on variation strategy, including whether to proceed to opinion, withdraw or resubmit, and coordinates the knock-on effects on labelling, national procedures and Greek reimbursement planning.

Contact PQRA to discuss your situation

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *